Vancouver, B.C.-based Neuromed Pharma ceuticals, a biopharmaceutical company that is developing chronic pain drugs, has completed enrollment in the phase III trial of Osmotic Release Oral Systems (OROS) Hydromorphone for the treatment of chronic moderate-to-severe low back pain in opioid-tolerant patients.

[News Source]